MARKET OUTLOOK
The Europe infertility (testing and treatment) market is expected to grow in terms of revenue at a CAGR of 6.37% during the forecasting period 2019-2027.
The UK, Spain, Germany, Italy, France, Russia and countries in rest of Europe have been considered for analysis on the report on Europe’s infertility (testing and treatment) market.
The accelerating success rates of IVF treatments in Germany has led to a significant growth of the infertility (testing and treatment) market. The high cost of the treatment and no reimbursement are the major restraints of the market. Until 2004, Germany was providing 100% coverage for IVF treatments. However, with the reduction of reimbursement amount to 50%, a significant decrease in IVF has been seen in Germany. The country has imposed coverage limits for both men (50 years) and women (40 years). Also, Germany bans the disposal and freezing of embryos because it defines an embryo as existing only after fertilization.
Today, on an average, 1 in every 100 babies in France is born through IVF. Moreover, France has shown better success rates in recent years as compared to other European neighbors such as the UK and Germany. Each year approximately 60,000 couples undergo infertility treatment in France. The average cost of an IVF cycle in France is lower than that in the UK. Moreover, France provides full coverage for IVF treatments or at least one cycle of IVF on a national basis. However, France does not recognize same-sex couples or single women as eligible for IVF within the social security system. If a woman is clinically obese (a BMI of 40 or over), she will be refused treatment and only woman below the age 43 years will fall under the coverage criteria.
COMPETITIVE OUTLOOK
Origio, The Cooper Companies, Inc., Ferring Pharmaceuticals, Progyny, Quest Diagnostic, Irvine Scientific, Esco Micro Pte. Ltd., Vitrolife AB, Ovascience, Merck, Thermo Fisher Scientific, Inc., Andrology Solutions, Genea, Endo Pharmaceuticals and Halotech DNA are the top key players in the market.